Introduction Body weight can affect exposure, safety and efficacy of antibody-based
therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved …

Panitumumab is a fully human monoclonal antibody targeted to the extracellular domain of
human epidermal growth factor receptor (EGFR). A comprehensive population …

Thank you for the opportunity to respond to the letter by Dr. Hendrikx and colleagues. We
wish to thank Dr. Hendrikx and colleagues for their interest in our recent publication by Liao …

Panitumumab is a recombinant, fully human IgG2 monoclonal antibody directed against the
epidermal growth factor receptor (EGFR). It is indicated for use as monotherapy in the …

With great interest we read the paper by Liao et al in which they compared a 2-weekly
bodyweight-based (6 mg/kg) and fixed (480 mg) administration of panitumumab, a …

Purpose This study evaluated safety, pharmacokinetics, and efficacy of 2 dose schedules
and 2 infusion times of panitumumab in patients with advanced solid malignancies. Patients …

Purpose: This phase 1 study evaluated the safety, pharmacokinetics, and activity of
panitumumab, a fully human, IgG2 monoclonal antibody that targets the epidermal growth …

Panitumumab is a fully human monoclonal antibody that binds to the epidermal growth
factor receptor (EGFR), thereby inhibiting the growth and survival of tumors expressing …

Purpose Panitumumab is used for the treatment for metastatic RAS wild-type colorectal
cancer (mCRC). It is likely that many of these patients will present with liver metastases and …

Background Panitumumab is a fully human, monoclonal antibody against the epidermal
growth factor receptor. Previous studies in non-Japanese patients with solid tumors showed …